Skip to main content
. Author manuscript; available in PMC: 2017 Aug 8.
Published in final edited form as: Am J Clin Oncol. 2014 Jun;37(3):261–265. doi: 10.1097/COC.0b013e318277d5c8

Table 1. Patients' Demographics on Both Arms of Study.

Characteristics IL-2 (n = 10) LMI+IL-2 (n=11) Test P
LDH level 674.8 ± 290.4
Median = 603.5		 516.1 ± 90.5
Median = 513.5		 Rank Sum 0.0917
No. prior therapies 1.2 ± 1.2
Median =1.0		 2.1 ± 2.0
Median = 1.5		 Rank Sum 0.3088
Time from last prior therapy (mo) 8.3 ± 15.1
Median = 2.4		 8.4 ± 15.5
Median = 2.0		 Rank Sum 0.9702
Time from diagnosis to study therapy (mo) 31.0 ± 21.2
Median = 30.4		 70.3 ± 121.3
Median= 35.0		 Rank Sum 0.4814
Primary site
 Eye 1 (50%) 1 (50%) Fisher exact 1.0000
 Mucosal 1 (50%) 1 (50%)
 Skin 8 (50%) 8 (50%)
ECOG performance
 0 9 (90%) 7 (70%) Fisher exact 0.5820
 1 1 (10%) 3 (30%)